25 XP   0   0   10

Chromadex Corp
Buy, Hold or Sell?

Let's analyse Chromadex together

PenkeI guess you are interested in Chromadex Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Chromadex Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Chromadex Corp

I send you an email if I find something interesting about Chromadex Corp.

Quick analysis of Chromadex (30 sec.)










What can you expect buying and holding a share of Chromadex? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.38
Expected worth in 1 year
$0.37
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-0.1%

For what price can you sell your share?

Current Price per Share
$3.69
Expected price per share
$2.24 - $4.65
How sure are you?
50%

1. Valuation of Chromadex (5 min.)




Live pricePrice per Share (EOD)

$3.69

Intrinsic Value Per Share

$-0.79 - $-0.73

Total Value Per Share

$-0.41 - $-0.35

2. Growth of Chromadex (5 min.)




Is Chromadex growing?

Current yearPrevious yearGrowGrow %
How rich?$28.4m$24m$3.6m13.1%

How much money is Chromadex making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$3m$2m183.7%
Net Profit Margin-5.3%-18.4%--

How much money comes from the company's main activities?

3. Financial Health of Chromadex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#542 / 1016

Most Revenue
#231 / 1016

Most Profit
#244 / 1016

Most Efficient
#465 / 1016

What can you expect buying and holding a share of Chromadex? (5 min.)

Welcome investor! Chromadex's management wants to use your money to grow the business. In return you get a share of Chromadex.

What can you expect buying and holding a share of Chromadex?

First you should know what it really means to hold a share of Chromadex. And how you can make/lose money.

Speculation

The Price per Share of Chromadex is $3.69. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Chromadex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Chromadex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.38. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Chromadex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.0%-0.02-0.4%-0.05-1.5%-0.07-1.8%-0.06-1.7%
Usd Book Value Change Per Share0.020.4%0.000.0%-0.01-0.3%0.000.0%0.010.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.020.4%0.000.0%-0.01-0.3%0.000.0%0.010.2%
Usd Price Per Share1.43-1.50-1.76-3.80-3.25-
Price to Earnings Ratio236.17-44.72--14.18--3.41--170.75-
Price-to-Total Gains Ratio93.81-119.35-84.57--6.77--14.58-
Price to Book Ratio3.78-4.07-5.51-11.37-14.24-
Price-to-Total Gains Ratio93.81-119.35-84.57--6.77--14.58-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.69
Number of shares271
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (271 shares)-0.190.23
Gains per Year (271 shares)-0.780.92
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1-1101-9
20-2-1202-8
30-2-1303-7
40-3-1404-6
50-4-1505-5
60-5-1606-4
70-5-1706-3
80-6-1807-2
90-7-1908-1
100-8-20090

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.037.00.07.5%4.065.00.05.8%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%7.013.00.035.0%16.024.00.040.0%27.040.02.039.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.069.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%7.013.00.035.0%16.024.00.040.0%27.040.02.039.1%

Fundamentals of Chromadex

About Chromadex Corp

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Fundamental data was last updated by Penke on 2024-04-11 03:50:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Chromadex Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Chromadex earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • A Net Profit Margin of 0.5% means that $0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Chromadex Corp:

  • The MRQ is 0.5%. The company is not making a profit/loss.
  • The TTM is -5.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ0.5%TTM-5.3%+5.8%
TTM-5.3%YOY-18.4%+13.1%
TTM-5.3%5Y-33.6%+28.4%
5Y-33.6%10Y-38.4%+4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5%-199.6%+200.1%
TTM-5.3%-213.0%+207.7%
YOY-18.4%-279.3%+260.9%
5Y-33.6%-438.4%+404.8%
10Y-38.4%-605.5%+567.1%
1.1.2. Return on Assets

Shows how efficient Chromadex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • 0.2% Return on Assets means that Chromadex generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Chromadex Corp:

  • The MRQ is 0.2%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -2.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.2%TTM-2.0%+2.3%
TTM-2.0%YOY-6.2%+4.1%
TTM-2.0%5Y-10.2%+8.2%
5Y-10.2%10Y-9.8%-0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2%-13.5%+13.7%
TTM-2.0%-12.9%+10.9%
YOY-6.2%-11.8%+5.6%
5Y-10.2%-14.1%+3.9%
10Y-9.8%-16.0%+6.2%
1.1.3. Return on Equity

Shows how efficient Chromadex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • 0.4% Return on Equity means Chromadex generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Chromadex Corp:

  • The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-4.0%+4.4%
TTM-4.0%YOY-13.3%+9.3%
TTM-4.0%5Y-20.7%+16.7%
5Y-20.7%10Y-19.0%-1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4%-16.9%+17.3%
TTM-4.0%-16.1%+12.1%
YOY-13.3%-15.1%+1.8%
5Y-20.7%-19.9%-0.8%
10Y-19.0%-20.9%+1.9%

1.2. Operating Efficiency of Chromadex Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Chromadex is operating .

  • Measures how much profit Chromadex makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • An Operating Margin of 1.1% means the company generated $0.01  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Chromadex Corp:

  • The MRQ is 1.1%. The company is operating less efficient.
  • The TTM is -6.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ1.1%TTM-6.7%+7.8%
TTM-6.7%YOY-27.5%+20.8%
TTM-6.7%5Y-35.9%+29.2%
5Y-35.9%10Y-41.3%+5.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1%-295.1%+296.2%
TTM-6.7%-225.8%+219.1%
YOY-27.5%-288.4%+260.9%
5Y-35.9%-477.4%+441.5%
10Y-41.3%-625.6%+584.3%
1.2.2. Operating Ratio

Measures how efficient Chromadex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.99 means that the operating costs are $0.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Chromadex Corp:

  • The MRQ is 0.989. The company is less efficient in keeping operating costs low.
  • The TTM is 1.062. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.989TTM1.062-0.073
TTM1.062YOY1.270-0.207
TTM1.0625Y1.351-0.289
5Y1.35110Y1.406-0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9893.090-2.101
TTM1.0623.264-2.202
YOY1.2703.783-2.513
5Y1.3515.679-4.328
10Y1.4067.894-6.488

1.3. Liquidity of Chromadex Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Chromadex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.40 means the company has $2.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Chromadex Corp:

  • The MRQ is 2.402. The company is able to pay all its short-term debts. +1
  • The TTM is 2.447. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.402TTM2.447-0.045
TTM2.447YOY2.357+0.091
TTM2.4475Y2.480-0.033
5Y2.48010Y2.698-0.217
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4023.914-1.512
TTM2.4474.220-1.773
YOY2.3575.388-3.031
5Y2.4806.045-3.565
10Y2.6986.406-3.708
1.3.2. Quick Ratio

Measures if Chromadex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • A Quick Ratio of 1.58 means the company can pay off $1.58 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Chromadex Corp:

  • The MRQ is 1.579. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.673. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.579TTM1.673-0.094
TTM1.673YOY1.328+0.345
TTM1.6735Y1.636+0.037
5Y1.63610Y1.851-0.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5793.572-1.993
TTM1.6733.998-2.325
YOY1.3285.390-4.062
5Y1.6365.969-4.333
10Y1.8516.287-4.436

1.4. Solvency of Chromadex Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Chromadex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Chromadex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.48 means that Chromadex assets are financed with 48.2% credit (debt) and the remaining percentage (100% - 48.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Chromadex Corp:

  • The MRQ is 0.482. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.485. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.482TTM0.485-0.003
TTM0.485YOY0.519-0.034
TTM0.4855Y0.485+0.000
5Y0.48510Y0.464+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4820.336+0.146
TTM0.4850.334+0.151
YOY0.5190.269+0.250
5Y0.4850.366+0.119
10Y0.4640.390+0.074
1.4.2. Debt to Equity Ratio

Measures if Chromadex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Chromadex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 93.2% means that company has $0.93 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Chromadex Corp:

  • The MRQ is 0.932. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.942. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.932TTM0.942-0.010
TTM0.942YOY1.087-0.145
TTM0.9425Y0.981-0.040
5Y0.98110Y1.023-0.041
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9320.382+0.550
TTM0.9420.396+0.546
YOY1.0870.335+0.752
5Y0.9810.434+0.547
10Y1.0230.465+0.558

2. Market Valuation of Chromadex Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Chromadex generates.

  • Above 15 is considered overpriced but always compare Chromadex to the Biotechnology industry mean.
  • A PE ratio of 236.17 means the investor is paying $236.17 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Chromadex Corp:

  • The EOD is 609.409. Based on the earnings, the company is expensive. -2
  • The MRQ is 236.167. Based on the earnings, the company is expensive. -2
  • The TTM is 44.717. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD609.409MRQ236.167+373.242
MRQ236.167TTM44.717+191.450
TTM44.717YOY-14.179+58.896
TTM44.7175Y-3.410+48.127
5Y-3.41010Y-170.746+167.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD609.409-2.259+611.668
MRQ236.167-2.569+238.736
TTM44.717-2.664+47.381
YOY-14.179-4.120-10.059
5Y-3.410-6.258+2.848
10Y-170.746-6.171-164.575
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Chromadex Corp:

  • The EOD is 125.629. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 48.685. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 35.670. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD125.629MRQ48.685+76.943
MRQ48.685TTM35.670+13.015
TTM35.670YOY-20.951+56.622
TTM35.6705Y88.033-52.362
5Y88.03310Y38.011+50.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD125.629-2.924+128.553
MRQ48.685-3.246+51.931
TTM35.670-3.488+39.158
YOY-20.951-5.620-15.331
5Y88.033-8.315+96.348
10Y38.011-8.826+46.837
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Chromadex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.78 means the investor is paying $3.78 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Chromadex Corp:

  • The EOD is 9.766. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.785. Based on the equity, the company is fair priced.
  • The TTM is 4.070. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD9.766MRQ3.785+5.981
MRQ3.785TTM4.070-0.285
TTM4.070YOY5.508-1.438
TTM4.0705Y11.375-7.305
5Y11.37510Y14.237-2.862
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.7661.851+7.915
MRQ3.7852.090+1.695
TTM4.0702.095+1.975
YOY5.5082.844+2.664
5Y11.3753.466+7.909
10Y14.2373.815+10.422
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Chromadex Corp.

3.1. Institutions holding Chromadex Corp

Institutions are holding 16.07% of the shares of Chromadex Corp.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc4.04750.0001304811944770.1471
2023-12-31Tieton Capital Management, LLC3.8692.3472291367546169218.8293
2023-12-31ICONIQ Capital, LLC1.72140.0346129635400
2023-12-31BlackRock Inc1.20130904692-2809-0.3095
2023-12-31Geode Capital Management, LLC0.66920.000150394300
2023-12-31Renaissance Technologies Corp0.62320.001469302243905.482
2023-12-31Gamco Investors, Inc. Et Al0.34740.00426165018000.6927
2023-12-31Gabelli Funds LLC0.26560.00222000002000011.1111
2023-12-31State Street Corporation0.2526019023900
2023-09-30Citadel Advisors Llc0.22940.0001172770-14443-7.7147
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC0.19790.0054149035101227.2866
2023-12-31Qube Research & Technologies0.1750.0004131794119184945.1546
2023-12-31Millennium Management LLC0.16610.0001125096-105601-45.7748
2023-12-31Royal Bank of Canada0.158101190423444840.7216
2023-12-31CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.15640.0007117790-5128-4.1719
2023-12-31Connor Clark & Lunn Inv Mgmt Ltd0.15470.00081165133348240.3247
2023-12-31Northern Trust Corp0.124909408400
2023-12-31Bank of New York Mellon Corp0.1144086147-239-0.2767
2023-12-31Silverberg Bernstein Capital Management LLC0.10990.112982757827570
2023-12-31Squarepoint Ops LLC0.08220.00026189936326.2334
Total 14.66622.509811044901+667764+6.0%

3.2. Funds holding Chromadex Corp

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Tieton Small Cap Value3.8692.2995291367546169218.8293
2024-02-29Vanguard Total Stock Mkt Idx Inv2.91660.0002219648400
2023-12-31Pleiades Small Cap Equity A1.10250.131983030015419022.8055
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.9930.001274781400
2024-02-29PA Ucits Food Revolution S USD0.41220.87383104007586632.3475
2024-02-29Fidelity Extended Market Index0.36010.0012271180-1314-0.4822
2023-12-31Acuitas US Microcap Institutional0.27590.4342077804054024.2406
2023-12-31Gabelli Equity Trust0.17260.00941300002000018.1818
2024-03-28iShares Micro-Cap ETF0.15550.044311710923142.0158
2023-09-30BlackRock Extended Mkt Composite0.1480.001211145700
2023-12-31GAMCO Small Cap Value0.13280.270510000000
2024-03-31BlackRock Extended Equity Market K0.12920.002397272350.036
2024-02-29Fidelity Total Market Index0.1080.00028132900
2023-12-31Gabelli Global Small & Mid Cap Value Tru0.0930.07577000000
2024-02-29Fidelity Series Total Market Index0.09050.00026813600
2024-02-29Vanguard Balanced Index Inv0.06290.00024740300
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06120.0014612500
2023-12-31Northern Trust Extended Eq Market Idx0.05720.00114310500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05720.00114310500
2024-02-29Fidelity Nasdaq Composite Index0.05640.00054249500
Total 11.25384.14958475169+753323+8.9%

3.3. Insider Transactions

Insiders are holding 41.186% of the shares of Chromadex Corp.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-01Brianna GerberBUY50001.41
2023-06-12Frank L Jaksch JrBUY70001.69
2023-05-31Robert N FriedBUY70001.42
2023-05-25Steven D RubinBUY70001.46

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Chromadex Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.015-0.001+105%-0.010+167%0.001+1697%0.008+101%
Book Value Per Share--0.3780.368+3%0.320+18%0.344+10%0.287+32%
Current Ratio--2.4022.447-2%2.357+2%2.480-3%2.698-11%
Debt To Asset Ratio--0.4820.485-1%0.519-7%0.485-1%0.464+4%
Debt To Equity Ratio--0.9320.942-1%1.087-14%0.981-5%1.023-9%
Dividend Per Share----0%-0%-0%-0%
Eps--0.002-0.016+1183%-0.055+3727%-0.067+4516%-0.065+4364%
Free Cash Flow Per Share--0.0070.023-68%-0.051+798%-0.043+688%-0.036+592%
Free Cash Flow To Equity Per Share--0.0070.023-68%-0.026+452%0.003+161%0.006+29%
Gross Profit Margin---56.193-9.559-83%-2.059-96%-1.171-98%3.975-1514%
Intrinsic Value_10Y_max---0.726--------
Intrinsic Value_10Y_min---0.788--------
Intrinsic Value_1Y_max---0.134--------
Intrinsic Value_1Y_min---0.136--------
Intrinsic Value_3Y_max---0.357--------
Intrinsic Value_3Y_min---0.362--------
Intrinsic Value_5Y_max---0.522--------
Intrinsic Value_5Y_min---0.534--------
Market Cap277890593.760+61%107692018.720112775383.240-5%132544023.040-19%286118113.372-62%244935329.850-56%
Net Profit Margin--0.005-0.053+1079%-0.184+3519%-0.336+6350%-0.384+7249%
Operating Margin--0.011-0.067+714%-0.275+2612%-0.359+3384%-0.413+3870%
Operating Ratio--0.9891.062-7%1.270-22%1.351-27%1.406-30%
Pb Ratio9.766+61%3.7854.070-7%5.508-31%11.375-67%14.237-73%
Pe Ratio609.409+61%236.16744.717+428%-14.179+106%-3.410+101%-170.746+172%
Price Per Share3.690+61%1.4301.498-5%1.760-19%3.799-62%3.252-56%
Price To Free Cash Flow Ratio125.629+61%48.68535.670+36%-20.951+143%88.033-45%38.011+28%
Price To Total Gains Ratio242.065+61%93.808119.354-21%84.572+11%-6.774+107%-14.585+116%
Quick Ratio--1.5791.673-6%1.328+19%1.636-3%1.851-15%
Return On Assets--0.002-0.020+1086%-0.062+3082%-0.102+5030%-0.098+4819%
Return On Equity--0.004-0.040+1094%-0.133+3421%-0.207+5259%-0.190+4844%
Total Gains Per Share--0.015-0.001+105%-0.010+167%0.001+1697%0.008+101%
Usd Book Value--28456000.00027732750.000+3%24087500.000+18%25909000.000+10%21602624.750+32%
Usd Book Value Change Per Share--0.015-0.001+105%-0.010+167%0.001+1697%0.008+101%
Usd Book Value Per Share--0.3780.368+3%0.320+18%0.344+10%0.287+32%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.002-0.016+1183%-0.055+3727%-0.067+4516%-0.065+4364%
Usd Free Cash Flow--553000.0001723500.000-68%-3858000.000+798%-3252200.000+688%-2720304.375+592%
Usd Free Cash Flow Per Share--0.0070.023-68%-0.051+798%-0.043+688%-0.036+592%
Usd Free Cash Flow To Equity Per Share--0.0070.023-68%-0.026+452%0.003+161%0.006+29%
Usd Market Cap277890593.760+61%107692018.720112775383.240-5%132544023.040-19%286118113.372-62%244935329.850-56%
Usd Price Per Share3.690+61%1.4301.498-5%1.760-19%3.799-62%3.252-56%
Usd Profit--114000.000-1091500.000+1057%-3096750.000+2816%-4797650.000+4308%-3793351.375+3428%
Usd Revenue--21196000.00020892500.000+1%18012500.000+18%16430850.000+29%11192097.700+89%
Usd Total Gains Per Share--0.015-0.001+105%-0.010+167%0.001+1697%0.008+101%
 EOD+4 -4MRQTTM+20 -14YOY+28 -65Y+27 -710Y+25 -9

4.2. Fundamental Score

Let's check the fundamental score of Chromadex Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15609.409
Price to Book Ratio (EOD)Between0-19.766
Net Profit Margin (MRQ)Greater than00.005
Operating Margin (MRQ)Greater than00.011
Quick Ratio (MRQ)Greater than11.579
Current Ratio (MRQ)Greater than12.402
Debt to Asset Ratio (MRQ)Less than10.482
Debt to Equity Ratio (MRQ)Less than10.932
Return on Equity (MRQ)Greater than0.150.004
Return on Assets (MRQ)Greater than0.050.002
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Chromadex Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.780
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  -1,418-484-1,902-289-2,1911,232-9591,073114
EBIT  -1,899-509-2,40892-2,3161,169-1,1471,379232
EBITDA  -1,444-524-1,96896-1,8721,173-6991,304605
Operating Income  -1,444-524-1,968-348-2,3161,169-1,1471,379232
Total Other Income Expense Net 2640665912563188-306-118
Net Income from Continuing Operations  -1,418-484-1,902-289-2,1911,232-9591,073114



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets54,964
Total Liabilities26,508
Total Stockholder Equity28,456
 As reported
Total Liabilities 26,508
Total Stockholder Equity+ 28,456
Total Assets = 54,964

Assets

Total Assets54,964
Total Current Assets49,534
Long-term Assets5,430
Total Current Assets
Cash And Cash Equivalents 27,325
Net Receivables 5,234
Inventory 14,525
Other Current Assets 2,450
Total Current Assets  (as reported)49,534
Total Current Assets  (calculated)49,534
+/-0
Long-term Assets
Property Plant Equipment 4,537
Intangible Assets 510
Long-term Assets Other 383
Long-term Assets  (as reported)5,430
Long-term Assets  (calculated)5,430
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,622
Long-term Liabilities5,886
Total Stockholder Equity28,456
Total Current Liabilities
Short-term Debt 702
Accounts payable 10,232
Other Current Liabilities 9,493
Total Current Liabilities  (as reported)20,622
Total Current Liabilities  (calculated)20,427
+/- 195
Long-term Liabilities
Capital Lease Obligations 3,277
Long-term Liabilities  (as reported)5,886
Long-term Liabilities  (calculated)3,277
+/- 2,609
Total Stockholder Equity
Common Stock75
Retained Earnings -190,460
Accumulated Other Comprehensive Income -4
Other Stockholders Equity 218,845
Total Stockholder Equity (as reported)28,456
Total Stockholder Equity (calculated)28,456
+/-0
Other
Capital Stock75
Cash and Short Term Investments 27,325
Common Stock Shares Outstanding 74,981
Current Deferred Revenue195
Liabilities and Stockholders Equity 54,964
Net Debt -24,048
Net Invested Capital 28,456
Net Working Capital 28,912
Property Plant and Equipment Gross 9,947
Short Long Term Debt Total 3,277



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-06-302006-03-31
> Total Assets 
0
0
11
11
9
4
1
1
5,402
5,548
4,083
4,083
3,540
3,507
3,565
4,287
7,387
7,015
6,507
7,212
7,062
7,306
6,270
12,925
10,196
9,431
9,035
10,717
10,945
7,779
8,987
8,472
8,878
8,699
11,608
10,985
14,223
15,047
18,749
16,534
17,780
18,764
19,752
21,051
32,920
41,802
62,724
57,445
52,168
47,022
42,232
41,925
44,542
43,139
40,247
35,610
41,992
37,415
38,358
68,993
65,842
60,452
57,840
52,930
46,613
45,665
54,057
53,768
53,171
53,483
54,964
54,96453,48353,17153,76854,05745,66546,61352,93057,84060,45265,84268,99338,35837,41541,99235,61040,24743,13944,54241,92542,23247,02252,16857,44562,72441,80232,92021,05119,75218,76417,78016,53418,74915,04714,22310,98511,6088,6998,8788,4728,9877,77910,94510,7179,0359,43110,19612,9256,2707,3067,0627,2126,5077,0157,3874,2873,5653,5073,5404,0834,0835,5485,4021149111100
   > Total Current Assets 
0
0
11
11
9
4
1
1
3,612
3,738
2,299
2,299
1,936
1,998
2,008
2,471
5,644
5,326
4,895
5,641
5,535
5,833
4,953
11,629
8,978
8,270
7,927
5,690
6,268
4,678
5,791
6,421
6,582
6,313
9,899
9,056
12,315
13,034
16,548
14,374
15,155
15,491
15,737
15,589
27,377
36,259
57,178
52,582
46,485
41,487
36,534
34,777
37,525
36,365
33,518
29,147
35,766
30,728
32,219
63,219
57,932
52,835
48,905
44,523
38,508
37,901
46,567
46,565
46,382
47,181
49,534
49,53447,18146,38246,56546,56737,90138,50844,52348,90552,83557,93263,21932,21930,72835,76629,14733,51836,36537,52534,77736,53441,48746,48552,58257,17836,25927,37715,58915,73715,49115,15514,37416,54813,03412,3159,0569,8996,3136,5826,4215,7914,6786,2685,6907,9278,2708,97811,6294,9535,8335,5355,6414,8955,3265,6442,4712,0081,9981,9362,2992,2993,7383,6121149111100
       Cash And Cash Equivalents 
0
0
11
11
9
4
1
1
2,416
2,420
1,126
1,126
607
501
471
539
3,382
2,986
2,226
2,896
2,045
2,069
420
5,805
2,213
1,237
520
967
827
1,087
2,261
1,925
1,281
1,204
3,965
3,216
5,699
4,709
5,550
2,996
3,370
2,265
1,642
1,185
14,139
24,000
45,389
41,037
33,389
28,214
22,616
19,127
19,560
18,679
18,812
13,608
18,690
15,278
16,497
44,491
38,578
32,902
28,019
20,793
16,872
13,062
20,241
23,141
26,254
26,621
27,325
27,32526,62126,25423,14120,24113,06216,87220,79328,01932,90238,57844,49116,49715,27818,69013,60818,81218,67919,56019,12722,61628,21433,38941,03745,38924,00014,1391,1851,6422,2653,3702,9965,5504,7095,6993,2163,9651,2041,2811,9252,2611,0878279675201,2372,2135,8054202,0692,0452,8962,2262,9863,3825394715016071,1261,1262,4202,4161149111100
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
750
751
752
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000075275175000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
504
532
349
349
419
500
498
769
846
584
1,002
1,238
842
649
724
1,401
988
1,203
1,941
2,697
3,060
1,026
1,054
1,667
2,121
2,529
1,907
2,234
3,099
3,785
2,451
4,330
6,794
6,511
5,852
5,045
4,579
4,920
5,338
4,823
5,192
4,849
4,415
5,382
5,792
6,042
2,175
3,558
3,954
3,214
2,694
4,647
5,999
5,295
5,226
6,310
4,228
4,744
8,482
9,221
6,118
5,601
5,234
5,2345,6016,1189,2218,4824,7444,2286,3105,2265,2955,9994,6472,6943,2143,9543,5582,1756,0425,7925,3824,4154,8495,1924,8235,3384,9204,5795,0455,8526,5116,7944,3302,4513,7853,0992,2341,9072,5292,1211,6671,0541,0263,0602,6971,9411,2039881,4017246498421,2381,00258484676949850041934934953250400000000
       Other Current Assets 
0
0
0
38
0
0
0
0
113
159
113
113
63
108
116
176
252
288
244
201
673
614
904
372
523
393
261
453
436
347
271
336
307
294
293
374
427
377
374
360
466
402
330
420
865
724
655
909
627
593
577
721
706
1,071
996
701
584
1,005
1,145
1,119
972
1,762
1,859
1,913
1,455
4,259
2,967
2,295
1,885
2,183
2,450
2,4502,1831,8852,2952,9674,2591,4551,9131,8591,7629721,1191,1451,0055847019961,07170672157759362790965572486542033040246636037437742737429329430733627134743645326139352337290461467320124428825217611610863113113159113000038000
   > Long-term Assets 
0
0
0
0
0
0
0
0
1,790
1,810
1,784
1,784
1,603
1,509
1,557
1,816
1,743
1,689
1,612
1,571
1,528
1,474
1,317
1,296
1,218
1,161
1,107
5,027
4,678
3,101
3,196
2,051
2,296
2,386
1,710
1,928
1,908
2,012
2,202
2,160
2,625
3,273
4,015
5,463
5,543
5,542
5,545
4,863
5,683
5,535
5,698
7,148
7,017
6,774
6,729
6,463
6,226
6,687
6,139
5,774
7,910
7,617
8,935
8,407
8,105
7,764
7,490
7,203
6,789
6,302
5,430
5,4306,3026,7897,2037,4907,7648,1058,4078,9357,6177,9105,7746,1396,6876,2266,4636,7296,7747,0177,1485,6985,5355,6834,8635,5455,5425,5435,4634,0153,2732,6252,1602,2022,0121,9081,9281,7102,3862,2962,0513,1963,1014,6785,0271,1071,1611,2181,2961,3171,4741,5281,5711,6121,6891,7431,8161,5571,5091,6031,7841,7841,8101,79000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
1,310
1,290
1,294
1,294
1,178
1,124
1,203
1,450
1,396
1,360
1,303
1,280
1,240
1,182
1,172
1,140
1,067
988
936
981
1,013
970
1,063
1,026
1,218
1,294
1,265
1,580
1,552
1,582
1,789
1,723
1,860
2,495
3,111
3,253
3,373
2,691
2,872
2,911
3,878
3,745
3,585
5,045
4,927
4,741
4,656
4,412
4,192
4,630
4,432
4,158
6,332
6,133
7,355
6,993
6,783
6,505
6,322
6,041
5,680
5,296
4,537
4,5375,2965,6806,0416,3226,5056,7836,9937,3556,1336,3324,1584,4324,6304,1924,4124,6564,7414,9275,0453,5853,7453,8782,9112,8722,6913,3733,2533,1112,4951,8601,7231,7891,5821,5521,5801,2651,2941,2181,0261,0639701,0139819369881,0671,1401,1721,1821,2401,2801,3031,3601,3961,4501,2031,1241,1781,2941,2941,2901,31000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
0
0
0
20
20
20
20
20
0
0
750
750
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000750750002020202020000200000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
430
478
445
445
383
352
321
334
315
296
278
259
256
248
100
99
95
141
136
171
166
188
202
199
256
267
296
291
298
371
354
358
511
496
486
1,834
1,768
1,710
1,651
1,593
1,536
1,521
1,547
1,496
1,434
1,373
1,311
1,249
1,189
1,147
1,082
1,022
961
908
857
808
758
714
671
630
591
552
510
5105525916306717147588088579089611,0221,0821,1471,1891,2491,3111,3731,4341,4961,5471,5211,5361,5931,6511,7101,7681,834486496511358354371298291296267256199202188166171136141959910024825625927829631533432135238344544547843000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
366
347
329
309
291
287
291
144
156
151
173
171
2,364
2,365
2,131
2,133
1,025
1,078
1,093
0
349
356
430
0
437
765
777
1
2,209
2,170
2,852
0
359
269
269
566
607
656
660
762
802
845
910
625
594
617
576
723
606
564
545
497
0
518
0
0
00518049754556460672357661759462591084580276266065660756626926935902,8522,1702,2091777765437043035634901,0931,0781,0252,1332,1312,3652,364171173151156144291287291309329347366000000000000000
> Total Liabilities 
0
0
1
1
1
1
0
3
3,387
3,201
2,334
2,334
2,308
2,397
2,518
3,154
1,809
1,886
1,571
2,196
2,585
2,753
3,709
4,659
4,592
4,202
5,041
3,983
3,753
4,510
3,321
3,677
4,560
4,196
7,610
7,296
10,326
10,711
13,475
10,106
5,332
6,906
9,778
11,679
7,201
8,064
8,890
10,781
11,668
13,620
15,054
20,948
29,397
15,997
19,802
19,062
20,411
17,928
21,934
25,161
23,700
25,003
26,113
27,053
25,835
24,642
25,385
25,751
26,021
26,175
26,508
26,50826,17526,02125,75125,38524,64225,83527,05326,11325,00323,70025,16121,93417,92820,41119,06219,80215,99729,39720,94815,05413,62011,66810,7818,8908,0647,20111,6799,7786,9065,33210,10613,47510,71110,3267,2967,6104,1964,5603,6773,3214,5103,7533,9835,0414,2024,5924,6593,7092,7532,5852,1961,5711,8861,8093,1542,5182,3972,3082,3342,3343,2013,38730111100
   > Total Current Liabilities 
0
0
1
1
1
1
0
3
3,127
2,968
2,073
2,073
2,073
2,170
2,152
2,578
1,258
1,364
1,139
1,778
2,193
2,390
3,343
4,284
4,254
3,901
4,763
3,646
3,362
4,111
2,838
3,236
3,980
3,582
4,981
4,772
5,032
5,881
9,587
6,707
4,788
6,356
8,869
10,745
6,260
7,209
8,088
10,084
10,956
12,960
14,440
15,547
24,211
11,023
15,063
14,466
16,042
13,015
16,476
19,756
16,229
17,770
17,613
18,694
17,725
16,727
17,869
18,423
19,061
19,444
20,622
20,62219,44419,06118,42317,86916,72717,72518,69417,61317,77016,22919,75616,47613,01516,04214,46615,06311,02324,21115,54714,44012,96010,95610,0848,0887,2096,26010,7458,8696,3564,7886,7079,5875,8815,0324,7724,9813,5823,9803,2362,8384,1113,3623,6464,7633,9014,2544,2843,3432,3902,1931,7781,1391,3641,2582,5782,1522,1702,0732,0732,0732,9683,12730111100
       Short-term Debt 
0
0
0
0
0
0
0
0
1,039
1,062
78
78
51
37
28
71
73
76
79
76
74
71
77
81
77
73
77
99
110
114
139
136
160
163
372
660
361
815
1,748
2,086
218
217
255
275
299
191
196
200
191
183
173
839
10,952
901
853
820
766
733
620
504
480
460
548
647
659
694
696
714
785
864
702
70286478571469669465964754846048050462073376682085390110,9528391731831912001961912992752552172182,0861,7488153616603721631601361391141109977737781777174767976737128375178781,0621,03900000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
223
0
0
0
1,529
2,086
218
217
599
641
692
552
506
458
410
0
0
675
9,987
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000009,987675004104585065526926415992172182,0861,5290002230000000000000000000000000000000000
       Accounts payable 
0
0
1
1
1
1
0
3
547
389
444
444
486
474
548
879
787
816
515
981
1,357
1,307
2,250
3,066
3,401
2,839
3,428
2,376
2,152
2,347
1,441
1,922
2,758
2,271
3,452
2,641
3,095
3,561
6,224
2,905
2,331
4,099
5,978
7,865
3,132
4,347
3,718
5,856
6,757
8,893
9,548
9,753
9,323
6,168
9,626
8,159
9,780
6,881
9,445
11,693
9,970
10,804
10,423
9,780
10,197
9,119
9,679
8,951
10,031
9,198
10,232
10,2329,19810,0318,9519,6799,11910,1979,78010,42310,8049,97011,6939,4456,8819,7808,1599,6266,1689,3239,7539,5488,8936,7575,8563,7184,3473,1327,8655,9784,0992,3312,9056,2243,5613,0952,6413,4522,2712,7581,9221,4412,3472,1522,3763,4282,8393,4013,0662,2501,3071,35798151581678787954847448644444438954730111100
       Other Current Liabilities 
0
0
0
0
0
0
0
0
1,225
1,203
1,551
34
1,472
1,473
1,448
1,519
326
383
371
468
603
712
816
917
606
732
947
856
763
990
712
789
799
923
923
1,078
1,348
1,268
1,342
1,377
1,976
1,762
2,246
2,206
2,325
2,350
3,860
3,826
3,823
3,729
4,444
4,592
3,643
3,693
4,415
5,249
5,246
5,173
6,133
7,328
5,569
6,331
6,481
8,126
6,696
6,756
7,337
8,610
8,079
9,193
9,493
9,4939,1938,0798,6107,3376,7566,6968,1266,4816,3315,5697,3286,1335,1735,2465,2494,4153,6933,6434,5924,4443,7293,8233,8263,8602,3502,3252,2062,2461,7621,9761,3771,3421,2681,3481,0789239237997897129907638569477326069178167126034683713833261,5191,4481,4731,472341,5511,2031,22500000000
   > Long-term Liabilities 
0
0
0
1
1
1
3
3
260
233
261
261
235
227
366
576
551
522
432
418
391
364
366
375
338
301
278
337
391
399
483
441
580
614
2,629
2,524
5,294
4,830
3,888
3,398
544
550
909
934
941
854
802
697
712
660
614
5,401
5,186
4,974
4,739
4,596
4,369
4,913
5,458
5,405
7,471
7,233
8,500
8,359
8,110
7,915
7,516
7,328
6,960
6,731
5,886
5,8866,7316,9607,3287,5167,9158,1108,3598,5007,2337,4715,4055,4584,9134,3694,5964,7394,9745,1865,4016146607126978028549419349095505443,3983,8884,8305,2942,5242,62961458044148339939133727830133837536636439141843252255157636622723526126123326033111000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
165
148
0
0
0
0
148
219
238
209
280
250
404
457
2,491
2,405
5,185
4,727
3,790
3,306
338
283
344
365
393
361
310
258
219
178
137
94
121
70
18
36
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000361870121941371782192583103613933653442833383,3063,7904,7275,1852,4052,491457404250280209238219148000014816500000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
318
312
303
234
236
227
215
201
185
167
149
130
118
153
190
203
192
175
157
138
118
109
103
98
93
206
267
565
569
548
494
492
439
493
482
477
3,962
3,873
3,873
3,873
3,873
3,820
3,820
4,441
4,441
4,441
4,346
4,346
4,346
4,228
4,228
3,955
0
3,806
0
0
003,80603,9554,2284,2284,3464,3464,3464,4414,4414,4413,8203,8203,8733,8733,8733,8733,9624774824934394924945485695652672069398103109118138157175192203190153118130149167185201215227236234303312318000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
227
216
0
0
0
0
130
119
152
191
203
191
175
157
138
119
109
103
98
93
206
267
565
569
548
494
492
439
493
482
477
3,962
3,873
3,873
3,873
3,873
3,820
3,820
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003,8203,8203,8733,8733,8733,8733,9624774824934394924945485695652672069398103109119138157175191203191152119130000021622700000000000000000000
> Total Stockholder Equity
0
0
10
10
8
4
0
-3
2,015
2,347
1,749
1,749
1,232
1,110
1,047
1,133
5,578
5,129
4,936
5,016
4,477
4,553
2,561
8,266
5,603
5,229
3,993
6,734
7,192
3,269
5,665
4,794
4,319
4,503
3,998
3,689
3,896
4,336
5,275
6,428
12,448
11,857
9,974
9,372
25,719
33,738
53,834
46,664
40,500
33,402
27,178
20,977
15,145
27,142
20,445
16,548
21,581
19,487
16,424
43,832
42,142
35,449
31,727
25,877
20,778
21,023
28,672
28,017
27,150
27,308
28,456
28,45627,30827,15028,01728,67221,02320,77825,87731,72735,44942,14243,83216,42419,48721,58116,54820,44527,14215,14520,97727,17833,40240,50046,66453,83433,73825,7199,3729,97411,85712,4486,4285,2754,3363,8963,6893,9984,5034,3194,7945,6653,2697,1926,7343,9935,2295,6038,2662,5614,5534,4775,0164,9365,1295,5781,1331,0471,1101,2321,7491,7492,3472,015-3048101000
   Common Stock
0
0
1
1
1
1
1
1
28
29
29
29
29
29
29
29
60
60
61
63
66
73
73
88
90
92
92
96
101
101
105
105
105
105
105
106
106
106
108
36
37
38
38
38
46
48
55
55
55
55
55
55
55
59
60
60
61
62
62
68
68
68
68
68
68
68
74
74
75
75
75
7575757474686868686868686262616060595555555555555548463838383736108106106106105105105105105101101969292908873736663616060292929292929292811111100
   Retained Earnings Total Equity00-189,615-187,424-185,493-184,075-183,090-176,693-168,953-163,628-154,772-149,206-141,825-135,728-131,513-127,802-121,900-113,047-105,845-98,090-89,753-81,535-72,930-64,880-56,601-47,779-49,916-47,152-45,224-43,077-42,122-42,040-42,295-40,869-40,865-40,550-39,524-38,297-37,637-35,984-34,136-33,412-32,162-31,141-29,7170000-15,563-13,15800000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
-1,240
-1,240
-1,370
-1,440
-1,510
-1,580
-1,660
-1,740
-1,760
-1,850
-1,930
-2,009
-2,088
-2,162
-2,243
-2,320
-2,400
-2,480
-2,540
-2,590
-2,650
0
-2,690
-2,740
-2,800
-2,810
-2,880
-2,950
-2,910
-2,970
0
0
-3,142
-3,142
0
0
0
0
0
0
-2,051
-2,051
0
0
-2,790
-2,790
-3
-3
-3
-2
-2
-2
-2
0
2
3
-3
0
-1
-1
-4
-4-1-10-3320-2-2-2-2-3-3-3-2,790-2,79000-2,051-2,051000000-3,142-3,14200-2,970-2,910-2,950-2,880-2,810-2,800-2,740-2,6900-2,650-2,590-2,540-2,480-2,400-2,320-2,243-2,162-2,088-2,009-1,930-1,850-1,760-1,740-1,660-1,580-1,510-1,440-1,370-1,240-1,2400000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,570
20,043
0
0
0
0
33,618
34,886
36,329
36,580
39,697
40,674
41,851
42,695
43,417
44,133
44,655
45,098
47,462
48,432
54,533
54,897
55,160
56,486
75,590
81,470
110,380
111,489
113,375
114,882
116,876
119,012
120,935
140,130
142,285
144,290
153,036
155,156
158,190
192,972
196,848
199,011
200,614
202,502
203,798
205,027
214,094
215,367
216,691
0
0
00216,691215,367214,094205,027203,798202,502200,614199,011196,848192,972158,190155,156153,036144,290142,285140,130120,935119,012116,876114,882113,375111,489110,38081,47075,59056,48655,16054,89754,53348,43247,46245,09844,65544,13343,41742,69541,85140,67439,69736,58036,32934,88633,618000020,04317,57000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
22
22
39
39
39
39
7,827
8,869
8,920
8,920
10,388
10,514
10,636
10,758
15,555
16,069
16,795
16,269
17,570
20,043
20,543
32,826
34,237
35,475
36,018
37,366
38,869
39,170
42,347
40,674
44,541
45,435
46,217
46,943
47,535
48,048
50,372
51,402
54,533
54,897
58,302
56,486
75,590
81,470
110,380
111,489
113,375
114,882
118,927
119,012
120,935
140,130
145,075
144,290
153,036
155,156
158,190
192,972
196,848
199,011
200,614
202,502
203,798
205,027
214,094
215,367
216,691
217,807
218,845
218,845217,807216,691215,367214,094205,027203,798202,502200,614199,011196,848192,972158,190155,156153,036144,290145,075140,130120,935119,012118,927114,882113,375111,489110,38081,47075,59056,48658,30254,89754,53351,40250,37248,04847,53546,94346,21745,43544,54140,67442,34739,17038,86937,36636,01835,47534,23732,82620,54320,04317,57016,26916,79516,06915,55510,75810,63610,51410,3888,9208,9208,8697,82739393939222200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue83,570
Cost of Revenue-32,790
Gross Profit50,78050,780
 
Operating Income (+$)
Gross Profit50,780
Operating Expense-52,679
Operating Income-1,899-1,899
 
Operating Expense (+$)
Research Development4,958
Selling General Administrative24,983
Selling And Marketing Expenses26,438
Operating Expense52,67956,379
 
Net Interest Income (+$)
Interest Income661
Interest Expense-0
Other Finance Cost-256
Net Interest Income405
 
Pretax Income (+$)
Operating Income-1,899
Net Interest Income405
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-4,9381,140
EBIT - interestExpense = -1,899
-4,938
-4,938
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-1,899-4,938
Earnings Before Interest and Taxes (EBITDA)-194
 
After tax Income (+$)
Income Before Tax-4,938
Tax Provision-0
Net Income From Continuing Ops-6,470-4,938
Net Income-4,938
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses85,469
Total Other Income/Expenses Net-3,039-405
 

Technical Analysis of Chromadex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Chromadex. The general trend of Chromadex is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Chromadex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Chromadex Corp.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.65.

The bearish price targets are: 2.37 > 2.28 > 2.24.

Tweet this
Chromadex Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Chromadex Corp. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Chromadex Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Chromadex Corp.

Chromadex Corp Daily Moving Average Convergence/Divergence (MACD) ChartChromadex Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Chromadex Corp. The current adx is .

Chromadex Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Chromadex Corp.

Chromadex Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Chromadex Corp.

Chromadex Corp Daily Relative Strength Index (RSI) ChartChromadex Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Chromadex Corp.

Chromadex Corp Daily Stochastic Oscillator ChartChromadex Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Chromadex Corp.

Chromadex Corp Daily Commodity Channel Index (CCI) ChartChromadex Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Chromadex Corp.

Chromadex Corp Daily Chande Momentum Oscillator (CMO) ChartChromadex Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Chromadex Corp.

Chromadex Corp Daily Williams %R ChartChromadex Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Chromadex Corp.

Chromadex Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Chromadex Corp.

Chromadex Corp Daily Average True Range (ATR) ChartChromadex Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Chromadex Corp.

Chromadex Corp Daily On-Balance Volume (OBV) ChartChromadex Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Chromadex Corp.

Chromadex Corp Daily Money Flow Index (MFI) ChartChromadex Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Chromadex Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Chromadex Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Chromadex Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.780
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Chromadex with someone you think should read this too:
  • Are you bullish or bearish on Chromadex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Chromadex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Chromadex Corp

I send you an email if I find something interesting about Chromadex Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Chromadex Corp.

Receive notifications about Chromadex Corp in your mailbox!